CCT-128930 is a pyrrolopyrimidine that inhibits Akt and exhibits anticancer chemotherapeutic activity. In hepatoma cancer cells, this compound induces G1 phase cell cycle arrest, apoptosis, and autophagy, upregulates expression of p21, p27, and p53, and suppresses cell proliferation. CCT-128930 also induces G1 phase cell cycle arrest in glioblastoma cells and limits tumor growth in animal models with breast cancer xenografts.
| Cas No. | 885499-61-6 |
|---|---|
| Purity | ≥98% |
| Formula | C18H20ClN5 |
| Formula Wt. | 341.84 |
| IUPAC Name | 4-(4-Chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinamine |
| Synonym | CCT128930 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | C1176 Info Sheet PDF |
|---|
Wang FZ, Chang ZY, Fei HR, et al. CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition. Biochimie. 2014 Aug;103:118-25. PMID: 24793486.
Yap TA, Walton MI, Hunter LJ, et al. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther. 2011 Feb;10(2):360-71. PMID: 21191045.
Caldwell JJ, Davies TG, Donald A, et al. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J Med Chem. 2008 Apr 10;51(7):2147-57. PMID: 18345609.
